Exciting new therapy for Waldenstrms macroglobulinemia: ibrutinib plus rituximab

Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenstrms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology As... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts